Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Chemical-drug catalogue
Loaded records: 4 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 4 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 陕西丽彩药业有限公司 | 酒泉大得利制药股份有限公司 | 国药准字H20265960 | 2026/09/15 | 5ml：依达拉奉10mg与右莰醇2.5mg | 按化学药品新注册分类批准的仿制药 | CDE |
| 南京优科制药有限公司 | 南京优科制药有限公司 | 国药准字H20265515 | 2026/08/04 | 5ml：依达拉奉10mg与右莰醇2.5mg | 按化学药品新注册分类批准的仿制药 | CDE |
| 福建大谱生物医药有限公司 | 成都百裕制药股份有限公司 | 国药准字H20265503 | 2026/08/04 | 5ml：依达拉奉10mg与右莰醇2.5mg | 按化学药品新注册分类批准的仿制药 | CDE |
| 九华华源药业（桂林）有限公司 | 广东星昊药业有限公司 | 国药准字H20265537 | 2026/08/04 | 5ml：依达拉奉10mg与右莰醇2.5mg | 按化学药品新注册分类批准的仿制药 | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 5 distinct approval numbers and 5 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 先声药业有限公司 | 国药准字H20200007 | 5ml∶依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010101594 | NHSA |
| 九华华源药业(桂林)有限公司 | 国药准字H20265537 | 5ml:依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010105075 | NHSA |
| 南京优科制药有限公司 | 国药准字H20265515 | 5ml:依达拉奉10mg与右莰醇 2.5mg | 乙 | XN07XXY322B004010180542 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20265960 | 5ml:依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010183540 | NHSA |
| 福建大谱生物医药有限公司 | 国药准字H20265503 | 5ml:依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010186007 | NHSA |
| 先声药业有限公司 | 国药准字H20200007 | 5ml∶依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010201594 | NHSA |
| 南京优科制药有限公司 | 国药准字H20265515 | 5ml:依达拉奉10mg与右莰醇 2.5mg | 乙 | XN07XXY322B004010280542 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20265960 | 5ml:依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010283540 | NHSA |
| 福建大谱生物医药有限公司 | 国药准字H20265503 | 5ml:依达拉奉10mg与右莰醇2.5mg | 乙 | XN07XXY322B004010286007 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 32 filings and 32 distinct first applicants.
Generic 32
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏万高药业股份有限公司 | CYHS2601155 | Generic | 2026/05/14 | Not stated by source | CDE |
| 上海宣泰医药科技股份有限公司;江苏奥赛康药业有限公司 | CYHS2601643 | Generic | 2026/07/09 | Not stated by source | CDE |
| 江苏联环药业股份有限公司 | CYHS2504501 | Generic | 2025/12/31 | Not stated by source | CDE |
| 江苏悦兴药业有限公司 | CYHS2601933 | Generic | 2026/08/07 | Not stated by source | CDE |
| 江苏正大丰海制药有限公司 | CYHS2503960 | Generic | 2025/11/14 | Not stated by source | CDE |
| 江苏神龙药业有限公司 | CYHS2601407 | Generic | 2026/06/15 | Not stated by source | CDE |
| 苏州天马医药集团天吉生物制药有限公司 | CYHS2602418 | Generic | 2026/09/28 | Not stated by source | CDE |
| 南通慧聚制药有限公司;成都市海通药业有限公司 | CYHS2600436 | Generic | 2026/02/11 | Not stated by source | CDE |
| 无锡凯夫制药有限公司 | CYHS2600891 | Generic | 2026/04/17 | Not stated by source | CDE |
| 重庆莱美药业股份有限公司 | CYHS2602424 | Generic | 2026/09/29 | Not stated by source | CDE |
| 北京华素制药股份有限公司 | CYHS2602420 | Generic | 2026/09/28 | Not stated by source | CDE |
| 华北制药股份有限公司 | CYHS2602168 | Generic | 2026/09/01 | Not stated by source | CDE |
| 山西普恒制药有限公司 | CYHS2601895 | Generic | 2026/08/04 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2601879 | Generic | 2026/08/03 | Not stated by source | CDE |
| 四川健林药业有限责任公司;峨眉山通惠制药有限公司 | CYHS2601575 | Generic | 2026/07/03 | Not stated by source | CDE |
| 四川益生智同医药生物科技发展有限公司;重庆博腾药业有限公司 | CYHS2601555 | Generic | 2026/07/01 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司 | CYHS2601487 | Generic | 2026/06/24 | Not stated by source | CDE |
| 内蒙古白医制药股份有限公司 | CYHS2601263 | Generic | 2026/06/04 | Not stated by source | CDE |
| 平光制药股份有限公司 | CYHS2601106 | Generic | 2026/05/13 | Not stated by source | CDE |
| 成都利尔药业有限公司 | CYHS2601103 | Generic | 2026/05/13 | Not stated by source | CDE |
| 黑龙江福和制药集团股份有限公司 | CYHS2600970 | Generic | 2026/04/27 | Not stated by source | CDE |
| 山东新时代药业有限公司 | CYHS2600926 | Generic | 2026/04/22 | Not stated by source | CDE |
| 上海浦津林州制药有限公司 | CYHS2600838 | Generic | 2026/04/11 | Not stated by source | CDE |
| 山东京卫制药有限公司 | CYHS2600802 | Generic | 2026/04/08 | Not stated by source | CDE |
| 山东百诺医药股份有限公司;桂林南药股份有限公司 | CYHS2600760 | Generic | 2026/04/01 | Not stated by source | CDE |
| 江西泰吉立生物制药有限公司 | CYHS2600589 | Generic | 2026/03/01 | Not stated by source | CDE |
| 中山万汉制药有限公司 | CYHS2600300 | Generic | 2026/01/29 | Not stated by source | CDE |
| 石药集团欧意药业有限公司 | CYHS2600189 | Generic | 2026/01/16 | Not stated by source | CDE |
| 四川科伦药业股份有限公司 | CYHS2600056 | Generic | 2026/01/07 | Not stated by source | CDE |
| 遂成药业股份有限公司 | CYHS2503903 | Generic | 2025/11/08 | Not stated by source | CDE |
| 海南合瑞制药股份有限公司 | CYHS2503747 | Generic | 2025/10/21 | Not stated by source | CDE |
| 杭州民生药业股份有限公司 | CYHS2501703 | Generic | 2025/05/10 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 27 filings and 27 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏万高药业股份有限公司 | CYHS2601155 | Generic | 2026/05/14 | Not stated by source | CDE |
| 上海宣泰医药科技股份有限公司;江苏奥赛康药业有限公司 | CYHS2601643 | Generic | 2026/07/09 | Not stated by source | CDE |
| 江苏悦兴药业有限公司 | CYHS2601933 | Generic | 2026/08/07 | Not stated by source | CDE |
| 江苏神龙药业有限公司 | CYHS2601407 | Generic | 2026/06/15 | Not stated by source | CDE |
| 苏州天马医药集团天吉生物制药有限公司 | CYHS2602418 | Generic | 2026/09/28 | Not stated by source | CDE |
| 南通慧聚制药有限公司;成都市海通药业有限公司 | CYHS2600436 | Generic | 2026/02/11 | Not stated by source | CDE |
| 无锡凯夫制药有限公司 | CYHS2600891 | Generic | 2026/04/17 | Not stated by source | CDE |
| 重庆莱美药业股份有限公司 | CYHS2602424 | Generic | 2026/09/29 | Not stated by source | CDE |
| 北京华素制药股份有限公司 | CYHS2602420 | Generic | 2026/09/28 | Not stated by source | CDE |
| 华北制药股份有限公司 | CYHS2602168 | Generic | 2026/09/01 | Not stated by source | CDE |
| 山西普恒制药有限公司 | CYHS2601895 | Generic | 2026/08/04 | Not stated by source | CDE |
| 浙江华海药业股份有限公司 | CYHS2601879 | Generic | 2026/08/03 | Not stated by source | CDE |
| 四川健林药业有限责任公司;峨眉山通惠制药有限公司 | CYHS2601575 | Generic | 2026/07/03 | Not stated by source | CDE |
| 四川益生智同医药生物科技发展有限公司;重庆博腾药业有限公司 | CYHS2601555 | Generic | 2026/07/01 | Not stated by source | CDE |
| 新乡市常乐制药有限责任公司 | CYHS2601487 | Generic | 2026/06/24 | Not stated by source | CDE |
| 内蒙古白医制药股份有限公司 | CYHS2601263 | Generic | 2026/06/04 | Not stated by source | CDE |
| 平光制药股份有限公司 | CYHS2601106 | Generic | 2026/05/13 | Not stated by source | CDE |
| 成都利尔药业有限公司 | CYHS2601103 | Generic | 2026/05/13 | Not stated by source | CDE |
| 黑龙江福和制药集团股份有限公司 | CYHS2600970 | Generic | 2026/04/27 | Not stated by source | CDE |
| 山东新时代药业有限公司 | CYHS2600926 | Generic | 2026/04/22 | Not stated by source | CDE |
| 上海浦津林州制药有限公司 | CYHS2600838 | Generic | 2026/04/11 | Not stated by source | CDE |
| 山东京卫制药有限公司 | CYHS2600802 | Generic | 2026/04/08 | Not stated by source | CDE |
| 山东百诺医药股份有限公司;桂林南药股份有限公司 | CYHS2600760 | Generic | 2026/04/01 | Not stated by source | CDE |
| 江西泰吉立生物制药有限公司 | CYHS2600589 | Generic | 2026/03/01 | Not stated by source | CDE |
| 中山万汉制药有限公司 | CYHS2600300 | Generic | 2026/01/29 | Not stated by source | CDE |
| 石药集团欧意药业有限公司 | CYHS2600189 | Generic | 2026/01/16 | Not stated by source | CDE |
| 四川科伦药业股份有限公司 | CYHS2600056 | Generic | 2026/01/07 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, supplements, notices and review changes are labelled separately.
This source was last successfully updated at 2026/11/04 18:32; current coverage may be incomplete.
-
2026/09/29Accepted
-
2026/09/28Accepted
-
2026/09/28Accepted
苏州天马医药集团天吉生物制药有限公司
CYHS2602418
Fact date: 2026/09/28 · Site observation date: 2026/10/21
View source ↗ -
2026/09/01Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/05 06:45
- Chemical-drug catalogue
- Last successful update: 2026/11/05 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/05 06:40
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/04 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-21 to 2026-11-05; 1 pages pending. Covers loaded notices only, not a complete historical approval database.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to 依达拉奉右莰醇注射用浓溶液
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Pilot subscription
Ongoing tracking for selected drugs
¥2,400/ year · pilot price
- A competitive ledger for up to 10 drugs, updated with daily data and available historical comparisons.
- Collected changes routed to designated responsible roles with the daily scheduled send.
- A forwardable weekly project-change digest, with sources for each record.
- Source dates and coverage gaps shown when collection is incomplete.
This form records an activation request; it does not charge or activate a subscription. History begins with records actually accumulated by this site. Scope is confirmed before activation.